Cellosaurus logo
expasy logo

Cellosaurus LA-N-6 (CVCL_1363)

[Text version]
Cell line name LA-N-6
Synonyms LAN-6; LAN6; LA-N-6(OAN)
Accession CVCL_1363
Resource Identification Initiative To cite this cell line use: LA-N-6 (RRID:CVCL_1363)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Characteristics: Neuroblastic type (N-type) (PubMed=15720811).
Characteristics: Has long and heterogeneous telomeres and no telomerase activity. Its telomeres shortens continuously at an average rate of 55 base pairs per population doubling (PubMed=28636942).
Doubling time: 3 days (PubMed=28636942); ~1 week (DSMZ=ACC-674).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Deep tyrosine phosphoproteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
Sequence variations
  • Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=28636942).
  • Mutation; HGNC; 427; ALK; Simple; p.Asp1091Asn (c.3271G>A); ClinVar=VCV000218628; Zygosity=Heterozygous (PubMed=18724359; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
Genome ancestry Source: PubMed=30894373

Origin% genome
African2.47
Native American23.6
East Asian, North3.12
East Asian, South0
South Asian0
European, North42.61
European, South28.2
Disease Neuroblastoma (NCIt: C3270)
Neuroblastoma (ORDO: Orphanet_635)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_C1HR (LA-N-6 MUT p53)
Sex of cell Male
Age at sampling 6Y
Category Cancer cell line
STR profile Source(s): COG; Cosmic-CLP; DepMap; DSMZ

Markers:
AmelogeninX
CSF1PO11,12
D2S133818,19
D3S135815
D5S81810,12
D7S82011,12
D8S117913,14
D13S31712
D16S53910,12
D18S5116
D19S43314
D21S1130,32.2
FGA18,21
Penta D13
Penta E7,12
TH016
TPOX8
vWA14,16

Run an STR similarity search on this cell line
Web pages http://www.cccells.org/dl/NB_Data_Sheets/LA-N-6_Cell_Line_Data_Sheet_COGcell_org.pdf
Publications

PubMed=8242562; DOI=10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E
Wada R.K., Seeger R.C., Brodeur G.M., Einhorn P.A., Rayner S.A., Tomayko M.M., Reynolds C.P.
Human neuroblastoma cell lines that express N-myc without gene amplification.
Cancer 72:3346-3354(1993)

DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

PubMed=11507071
Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P.
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Cancer Res. 61:6185-6193(2001)

PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809
Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Cancer Res. 64:3395-3405(2004)

PubMed=15720811; DOI=10.1593/neo.04310
Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F., Biedler J.L., Cheung N.-K.V., Ross R.A.
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Neoplasia 6:838-845(2004)

PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)

PubMed=16822308; DOI=10.1186/1471-2407-6-177
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006)

PubMed=18724359; DOI=10.1038/nature07261
Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M.
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature 455:930-935(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=23202128; DOI=10.1038/ng.2493
Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y., Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Nat. Genet. 45:12-17(2013)

PubMed=24792489; DOI=10.1007/s11060-014-1456-8
Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P., Lau L.M.S.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
J. Neurooncol. 119:17-26(2014)

PubMed=25884760; DOI=10.1371/journal.pcbi.1004130
Palacios-Moreno J., Foltz L., Guo A.-L., Stokes M.P., Kuehn E.D., George L., Comb M.J., Grimes M.L.
Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts.
PLoS Comput. Biol. 11:e1004130.1-e1004130.33(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28350380; DOI=10.1038/sdata.2017.33
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017)

PubMed=28636942; DOI=10.1016/j.celrep.2017.05.087
Dagg R.A., Pickett H.A., Neumann A.A., Napier C.E., Henson J.D., Teber E.T., Arthur J.W., Reynolds C.P., Murray J., Haber M., Sobinoff A.P., Lau L.M.S., Reddel R.R.
Extensive proliferation of human cancer cells with ever-shorter telomeres.
Cell Rep. 19:2544-2556(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31631027; DOI=10.1016/j.ccell.2019.09.002
Qadeer Z.A., Valle-Garcia D., Hasson D., Sun Z., Cook A., Nguyen C., Soriano A., Ma A.-Q., Griffiths L.M., Zeineldin M., Filipescu D., Jubierre L., Chowdhury A., Deevy O., Chen X., Finkelstein D.B., Bahrami A., Stewart E., Federico S.M., Gallego S., Dekio F., Fowkes M., Meni D., Maris J.M., Weiss W.A., Roberts S.S., Cheung N.-K.V., Jin J., Segura M.F., Dyer M.A., Bernstein E.
ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures.
Cancer Cell 36:512-527.e9(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) DSMZ; ACC-674
Cell line databases/resources CLO; CLO_0037081
cancercelllines; CVCL_1363
Cell_Model_Passport; SIDM00330
Cosmic-CLP; 949170
DepMap; ACH-001355
DSMZCellDive; ACC-674
LINCS_LDP; LCL-1988
Biological sample resources BioSample; SAMN03473429
Chemistry resources ChEMBL-Cells; CHEMBL3308206
ChEMBL-Targets; CHEMBL2366123
GDSC; 949170
PharmacoDB; LAN6_819_2019
PubChem_Cell_line; CVCL_1363
Encyclopedic resources Wikidata; Q54901879
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM1670032
GEO; GSM2371240
GEO; GSM2394373
Polymorphism and mutation databases Cosmic; 697283
Cosmic; 717430
Cosmic; 848929
Cosmic; 930067
Cosmic; 949170
Cosmic; 1019942
Cosmic; 1109105
Cosmic; 1109366
Cosmic; 1161993
Cosmic; 1167408
Cosmic; 1526630
Cosmic; 1890102
Cosmic; 2301577
Cosmic; 2393637
IARC_TP53; 23822
IARC_TP53; 27562
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number39